NEWS!!!PHAR GOING FAAR!!
PharmStar Pharmaceuticals Announces the Formation of Its Medical Advisory Board
WILSON, NC, Jun 07, 2011 (MARKETWIRE via COMTEX) -- PharmStar Pharmaceuticals, Inc. (PINKSHEETS: PHAR) (the "Company") today announced that it has begun to form a Medical Advisory Board as part of its plan to roll out Aquaprin in 2012. This board will consist of up to 6 physicians that will advise the Company's Board of Directors in making its initial offering of Aquaprin and Intsa-Prin to the medical community, including hospitals, nursing homes, doctors offices, and emergency vehicles, such as police and ambulance services. This advisory board will also recommend and direct testing protocol for making the substantially improved claims over any other over the counter pain relievers.
Additionally, one member of the medical advisory board will be seated on the Board of Directors of the Company. That representative will represent the medical community in the Company's governing body.
CEO Howard Phykitt stated, "Now that the Company is moving forward with implementing its operational objectives, we believe that it is now time to start building its governance bodies and management staff so that we may timely meet the Company's goals. First and foremost, the Company will place enormous value on the guidance of those to whom the marketplace will look to for affirmation of our product. It is my considered opinion that by including the medical community early in our corporate development, we will not only gain valuable and credible minds to aid the Company with the medical fields acceptance and the distribution strategy, but we will also begin the process of educating the most crucial participants to the development of the Company's market -- the physicians and emergency services themselves. The marketplace will be looking to this group in general, but its patients will be looking to them directly. We have determined that the most reasonable course of action is also the most simple; allow those who have the greatest expertise in the application of medicine to not only confirm the value of our product, but also assist the Company in getting Aquaprin to a market that desperately needs an extremely fast acting soluble aspirin product."
When the members of the advisory board are fully appointed, the Company will name The Chairman of its Medical Advisory Board, who will also serve as the newest member of its Board of Directors.
About PharmStar Pharmaceuticals PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin(TM), an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin(TM) is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Wilson, NC. For more information, visit www.pharmstarinc.com.
Forward-Looking Statements Disclosure This press release includes "forward-looking statements" within the meaning of federal securities laws, commonly identified by such terms as "believes," "will," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
Contact:
PharmStar, Inc.
919-794-7000
Email Contact
